Literature DB >> 10408686

Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis.

P N Post1, D Stockton, T W Davies, J W Coebergh.   

Abstract

Increased awareness and improved diagnostic techniques have led to earlier diagnosis of prostate cancer and increased detection of subclinical cases, resulting in improved prognosis. We postulated that the considerable increase in incidence under age 60 is not attributable only to increased detection. To test this hypothesis, we studied incidence, mortality and relative survival among middle-aged patients diagnosed in south-east Netherlands and East Anglia (UK) between 1971 and 1994. Prostate-specific antigen (PSA) testing did not occur before 1990. Between 1971 and 1989, the age-standardized incidence at ages 40-59 increased from 8.8 to 12.5 per 10(5) in The Netherlands and from 7.0 to 11.6 per 10(5) in East Anglia. Five-year relative survival did not improve in East Anglia and even declined in southeast Netherlands from 65% [95% confidence interval (CI) 47-83) in 1975-79 to 48% (CI 34-62) in 1985-89. Mortality due to prostate cancer among men aged 45-64 years increased by 50% in south-east Netherlands and by 61% in East Anglia between 1971 and 1989, but decreased slightly in the 1990s. Because other factors adversely influencing the prognosis are unlikely, our results indicate an increase in the incidence of fatal prostate cancer among younger men in the era preceding PSA testing.

Entities:  

Mesh:

Year:  1999        PMID: 10408686      PMCID: PMC2362175          DOI: 10.1038/sj.bjc.6690004

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  The relative survival rate: a statistical methodology.

Authors:  F EDERER; L M AXTELL; S J CUTLER
Journal:  Natl Cancer Inst Monogr       Date:  1961-09

2.  Smoking and fatal prostate cancer in a large cohort of adult men.

Authors:  C Rodriguez; L M Tatham; M J Thun; E E Calle; C W Heath
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

3.  Cancer of the prostate in Norway 1957-1991--a descriptive study.

Authors:  S Harvei; S Tretli; F Langmark
Journal:  Eur J Cancer       Date:  1996-01       Impact factor: 9.162

4.  Cancer mortality rates fall: a turning point for the nation.

Authors:  M J Hoeksema; C Law
Journal:  J Natl Cancer Inst       Date:  1996-12-04       Impact factor: 13.506

5.  Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors.

Authors:  F Helgesen; L Holmberg; J E Johansson; R Bergström; H O Adami
Journal:  J Natl Cancer Inst       Date:  1996-09-04       Impact factor: 13.506

6.  Mortality trend from prostate cancer in The Netherlands (1950-1989).

Authors:  J W van der Gulden; L A Kiemeney; A L Verbeek; H Straatman
Journal:  Prostate       Date:  1994       Impact factor: 4.104

7.  Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995.

Authors:  P N Post; P J Kil; M A Crommelin; R F Schapers; J W Coebergh
Journal:  Eur J Cancer       Date:  1998-04       Impact factor: 9.162

8.  Striking changes in smoking behaviour and lung cancer incidence by histological type in south-east Netherlands, 1960-1991.

Authors:  M L Janssen-Heijnen; H W Nab; J van Reek; L H van der Heijden; R Schipper; J W Coebergh
Journal:  Eur J Cancer       Date:  1995-06       Impact factor: 9.162

9.  A computer program package for relative survival analysis.

Authors:  T Hakulinen; K H Abeywickrama
Journal:  Comput Programs Biomed       Date:  1985

10.  The role of increasing detection in the rising incidence of prostate cancer.

Authors:  A L Potosky; B A Miller; P C Albertsen; B S Kramer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

View more
  4 in total

1.  Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis.

Authors:  Hani Ashamalla; Adel Guirguis; Kyle McCool; Shauna McVorran; Malcolm Mattes; Daniel Metzger; Clara Oromendia; Karla V Ballman; Bahaa Mokhtar; Mounzer Tchelebi; Evangelia Katsoulakis; Sameer Rafla
Journal:  Brachytherapy       Date:  2017-01-27       Impact factor: 2.362

2.  Her-2/neu oncogene amplification in clinically localised prostate cancer.

Authors:  J D Oxley; M H Winkler; D A Gillatt; D S Peat
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

3.  [Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].

Authors:  K Herkommer; T Paiss; M Merz; J E Gschwend; M Kron
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

4.  Androgen deprivation and cognition in prostate cancer.

Authors:  E Salminen; R Portin; J Korpela; H Backman; L-M Parvinen; H Helenius; M Nurmi
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.